nach oben

Erschienen in:

01.03.2016 | RADIOTHERAPY

Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy

verfasst von: Davide Franceschini, Fabiola Paiar, Calogero Saieva, Pierluigi Bonomo, Benedetta Agresti, Icro Meattini, Daniela Greto, Monica Mangoni, Fiammetta Meacci, Mauro Loi, Giacomo Zei, Lorenzo Livi, Giampaolo Biti

Erschienen in: La radiologia medica | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was undertaken to evaluate the association of individual parameters and outcome in patients with unresectable locally advanced head and neck cancer treated with radiochemotherapy.

Materials and methods

We retrospectively reviewed data from 126 patients treated in our Institution between 1998 and 2010 for a locally advanced head and neck cancer. Sixteen individual parameters were evaluated for association with specific outcomes such as overall survival, persistence of disease, disease-specific survival and disease-free survival.

Results

Six factors influenced overall survival on Kaplan–Meier survival analysis and on univariate Cox regression analysis: smoking, body mass index, site, haemoglobin (Hb) nadir, total dose of radiotherapy and comorbidities. On a multivariate logistic model with stepwise selection, comorbidities, body mass index, total dose and site maintained significance. A significant association for persistence of disease was found with smoking, Hb nadir and site of cancer on univariate and multivariate analysis. Disease-free survival was correlated with performance status, Hb nadir and comorbidities using Kaplan–Meier survival analysis and on univariate Cox regression analysis. Only performance status maintained the significance on multivariate analysis. Disease-specific survival was correlated with five parameters: body mass index, site, Hb nadir, therapy interruption and total dose; on multivariate analysis, Hb nadir, therapy interruption and site maintained a statistically significant association.

Conclusions

Hb nadir during treatment, body mass index, smoking, stage, comorbidities and performance status are prognostic factors of outcome and response to radical treatment with radiochemotherapy.

Bernier J, Domenge C, Ozsahin M et al (2004) European organization for research and treatment of cancer trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952CrossRefPubMed

Cooper JS, Pajak TF, Forastiere AA et al (2004) Radiation therapy oncology group 9501/intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944CrossRefPubMed

Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German cancer society 95–06 prospective randomized trial. J Clin Oncol 23:1125–1135CrossRefPubMed

Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed

Bourhis J, Overgaard J, Audry H et al (2006) Meta-analysis of radiotherapy in carcinomas of head and neck (MARCH) collaborative group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854CrossRefPubMed

Edge SB, Byrd DR, Compton CC (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York, pp 41–56

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

Bøje CR (2014) Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma—a systematic review. Radiother Oncol 110:81–90CrossRefPubMed

Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13:139–168CrossRefPubMed

10.

Harrison LB, Shasha D, Homel P (2003) Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 63(suppl 2):11–18

11.

Molls M, Stadler P, Becker A et al (1998) Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 174(suppl 4):13–16PubMed

12.

Denis F, Garaud P, Bardet E et al (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 22:69–76CrossRefPubMed

13.

Fukada J, Shigematsu N, Takeda A et al (2010) Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single institution study. Int J Radiat Oncol Biol Phys 76:417–424CrossRefPubMed

14.

Dietl B, Marienhagen J, Schäfer C, Kölbl O (2007) The prognostic value of anaemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy. Clin Oncol 19:228–233CrossRef

15.

Reichel O, Panzer M, Wimmer C et al (2003) Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors. Eur Arch Otorhinolaryngol 260:248–253PubMed

16.

van de Pol SM, Doornaert PA, de Bree R et al (2006) The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 42:131–138CrossRefPubMed

17.

Hirst DG, Wood PJ (1987) The adaptive response of mouse tumours to anaemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med 51:597–609CrossRefPubMed

18.

Cairns RA, Hill RP (2004) Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 64:2054–2061CrossRefPubMed

19.

Hilgert E, Bergmann C, Fichtner A, Gires O, Issing W (2009) Tobacco abuse relates to significantly reduced survival of patients with oropharyngeal carcinomas. Eur J Cancer Prev 18:120–126CrossRefPubMed

20.

Hoff CM, Grau C, Overgaard J (2012) Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma–a prospective study. Radiother Oncol 103:38–44CrossRefPubMed

21.

Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066–4074CrossRefPubMed

22.

Overgaard J, Hansen HS, Overgaard M et al (1998) A randomized double-blind phase III study of nimorazole as hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results from the Danish head and neck cancer study (DAHANCA). Protocol 5–85. Radiother Oncol 46:135–146CrossRefPubMed

23.

Janssens GO, Rademakers SE, Terhaard CH et al (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30:1777–1783CrossRefPubMed

24.

Rischin D, Peters L, Fisher R et al (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman radiation oncology group (TROG 98.02). J Clin Oncol 23:79–87CrossRefPubMed

25.

Hoskin PJ, Robinson M, Slevin N et al (2009) Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 27:5751–5756CrossRefPubMed

26.

Lambin P, Ramaekers BL, van Mastrigt GA et al (2009) Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 8:CD006158

27.

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCentralCrossRefPubMed

28.

Lassen P, Eriksen JG, Krogdahl A et al (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomized DAHANCA 6&7 trial. Radiother Oncol 100:49CrossRefPubMed

29.

Hong AM, Martin A, Armstrong BK et al (2013) Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 24:215–219CrossRefPubMed

30.

Zhu X, Zhang F, Zhang W et al (2013) Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol 108:387–397CrossRefPubMed

31.

Zang J, Li C, Zhao LN et al (2013) Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: a meta-analysis. Head Neck 35:1507–1514PubMed

Titel: Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy
verfasst von: Davide Franceschini
Fabiola Paiar
Calogero Saieva
Pierluigi Bonomo
Benedetta Agresti
Icro Meattini
Daniela Greto
Monica Mangoni
Fiammetta Meacci
Mauro Loi
Giacomo Zei
Lorenzo Livi
Giampaolo Biti
Publikationsdatum: 01.03.2016
Verlag: Springer Milan
Erschienen in: La radiologia medica / Ausgabe 3/2016
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-015-0586-1

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy